GRANDE PHARMACIE DIJONNAISE : revenue, balance sheet and financial ratios

GRANDE PHARMACIE DIJONNAISE is a French company founded 19 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in DIJON (21000), this company of category PME shows in 2021 a revenue of 2.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - GRANDE PHARMACIE DIJONNAISE (SIREN 499222289)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue N/C N/C N/C N/C 2 838 492 € 2 535 880 € 2 555 021 € 2 579 050 € 1 263 116 € 2 277 496 € 2 204 721 €
Net income 122 126 € 121 449 € 114 578 € 256 052 € 161 490 € 100 645 € 124 819 € 135 227 € 37 478 € 29 141 € -43 216 €
EBITDA N/C N/C N/C N/C 243 675 € 154 638 € 203 842 € 188 269 € 72 942 € 102 982 € 16 387 €
Net margin N/C N/C N/C N/C 5.7% 4.0% 4.9% 5.2% 3.0% 1.3% -2.0%

Revenue and income statement

In 2025, GRANDE PHARMACIE DIJONNAISE generates positive net income of 122 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

122 126 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 19%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 51%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

19.146%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

51.351%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

21.4%

Solvency indicators evolution
GRANDE PHARMACIE DIJONNAISE

Sector positioning

Debt ratio
19.15 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good

In 2025, the debt ratio of GRANDE PHARMACIE DIJONNAISE (19.15) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
51.35% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average -7 pts over 3 years

In 2025, the financial autonomy of GRANDE PHARMACIE DIJONNAISE (51.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 121.02. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

121.015

Liquidity indicators evolution
GRANDE PHARMACIE DIJONNAISE

Sector positioning

Liquidity ratio
121.02 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch -6 pts over 3 years

In 2025, the liquidity ratio of GRANDE PHARMACIE DIJONNAISE (121.02) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
GRANDE PHARMACIE DIJONNAISE

Positioning of GRANDE PHARMACIE DIJONNAISE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of GRANDE PHARMACIE DIJONNAISE is estimated at 1 939 986 € (range 1 316 483€ - 3 044 105€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1316k€ 1939k€ 3044k€
1 939 986 € Range: 1 316 483€ - 3 044 105€
NAF 5 année 2025

Valuation method used

Net Income Multiple
122 126 € × 15.9x = 1 939 986 €
Range: 1 316 484€ - 3 044 105€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare GRANDE PHARMACIE DIJONNAISE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about GRANDE PHARMACIE DIJONNAISE

What is the revenue of GRANDE PHARMACIE DIJONNAISE ?

The revenue of GRANDE PHARMACIE DIJONNAISE in 2021 is 2.8 M€.

Is GRANDE PHARMACIE DIJONNAISE profitable?

Yes, GRANDE PHARMACIE DIJONNAISE generated a net profit of 122 k€ in 2025.

Where is the headquarters of GRANDE PHARMACIE DIJONNAISE ?

The headquarters of GRANDE PHARMACIE DIJONNAISE is located in DIJON (21000), in the department Cote-d'Or.

Where to find the tax return of GRANDE PHARMACIE DIJONNAISE ?

The tax return of GRANDE PHARMACIE DIJONNAISE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does GRANDE PHARMACIE DIJONNAISE operate?

GRANDE PHARMACIE DIJONNAISE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.